Related by context. All words. (Click for frequent words.) 76 chemoradiotherapy 75 neoadjuvant chemotherapy 73 neoadjuvant 73 adjuvant radiotherapy 73 ZACTIMA 72 Doxil ® 72 concurrent chemoradiation 71 neoadjuvant therapy 71 Neoadjuvant 70 chemoradiation therapy 70 preoperative chemotherapy 70 capecitabine Xeloda 69 sunitinib malate 69 debulking surgery 69 relapsed MM 69 postoperative chemotherapy 69 metastatic RCC 69 ixabepilone 69 sorafenib Nexavar 69 pertuzumab 69 recurrent GBM 69 chemoradiation 69 FOLPI 69 HER2 positive metastatic breast 68 estramustine 68 papillary renal cell carcinoma 68 recurrent glioblastoma multiforme 68 nonmetastatic 68 colorectal liver metastases 68 pancreatic adenocarcinoma 68 histologically confirmed 68 metastatic pancreatic 68 ASCT 68 cisplatin gemcitabine 68 NMIBC 68 thalidomide Thalomid 68 recurrent metastatic 68 CLL SLL 68 adjuvant therapy 68 recurrent NSCLC 68 assessing T DM1 68 Xelox 67 liver resection 67 receptor tyrosine kinase inhibitor 67 heavily pretreated patients 67 unresectable tumors 67 metastatic malignant 67 cisplatin chemotherapy 67 taxane therapy 67 pegylated liposomal doxorubicin 67 mycophenolate mofetil 67 cytoreduction 67 eribulin mesylate 67 Pemetrexed 67 MGd 67 adjuvant radiation 67 LHRH receptor positive 67 pegylated interferon alfa 2b 67 Hormone Refractory Prostate Cancer 67 pain palliation 67 adjuvant tamoxifen 67 gefitinib Iressa 67 stage IIIB 67 Adjuvant chemotherapy 67 galiximab 67 curative resection 67 metastatic CRC 67 advanced hepatocellular carcinoma 67 erlotinib Tarceva ® 67 renal tumors 67 carboplatin paclitaxel 66 non resectable 66 invasive lobular carcinoma 66 adjuvant hormonal therapy 66 ER CHOP 66 resectable 66 docetaxel Taxotere 66 Zarnestra 66 platinum refractory 66 ABVD 66 DOXIL 66 locoregional 66 Flu Cy 66 metastatic gastric 66 relapsed ovarian cancer 66 ara C 66 sentinel lymph node biopsy 66 gemcitabine chemotherapy 66 neratinib 66 Surgical resection 66 NSABP 66 BCG refractory 66 stage IIIb IV 66 demonstrated antitumor activity 66 metastatic GIST 66 Pegylated Liposomal Doxorubicin 66 gemcitabine Gemzar 66 lymph node dissection 66 underwent resection 66 anthracyclines taxanes 66 gemcitabine carboplatin 66 #F FDG PET 66 adjuvant chemotherapy 66 surgical debulking 66 nab paclitaxel 66 cediranib 66 TTF Therapy 66 adjuvant endocrine therapy 66 Pertuzumab 66 external beam radiotherapy 66 biliary tract cancer 66 metastatic renal cell carcinoma 66 radiotherapy RT 66 Tarceva TM 66 locoregional recurrence 66 refractory colorectal cancer 66 liposomal doxorubicin 65 intraperitoneal chemotherapy 65 postoperative radiotherapy 65 CRp 65 PROLARIS 65 prostate cancer CaP 65 chemotherapy cisplatin 65 SYN# 65 basal cell carcinoma BCC 65 trastuzumab Herceptin 65 ErbB2 positive 65 pomalidomide 65 MAGE A3 ASCI 65 vandetanib 65 BCIRG 65 anti angiogenic therapy 65 cytoreductive nephrectomy 65 Degarelix 65 paclitaxel carboplatin 65 refractory metastatic 65 SLNB 65 medically inoperable 65 intra arterial chemotherapy 65 lymphoid malignancies 65 CYT# potent vascular disrupting 65 antiangiogenic therapy 65 liver metastasis 65 anthracycline taxane 65 enzastaurin 65 biochemical relapse 65 Acute Coronary Syndromes ACS 65 fallopian tube carcinoma 65 antiretroviral naïve 65 malignant pleural mesothelioma 65 depsipeptide 65 chemoembolization 65 paclitaxel Taxol 65 tamoxifen therapy 65 TORISEL 65 YONDELIS 65 lymphadenectomy 65 SWOG 65 nonmetastatic prostate cancer 65 RTOG 65 Velcade bortezomib 65 androgen suppression 65 epirubicin cyclophosphamide 65 comparator arm 65 FOLFOX6 65 histological subtype 65 STRIDE PD 65 gemcitabine Gemzar ® 65 HIPEC 65 epirubicin 65 metastatic hormone refractory 65 ORAL HYCAMTIN 65 chemotherapy docetaxel 65 BRAF inhibitor 65 clinically localized prostate 65 Capecitabine 65 XELOX 65 FDG-PET/CT 65 metastatic bladder 65 trabectedin 64 colorectal cancer liver metastases 64 hormone receptor negative 64 pegylated liposomal doxorubicin PLD 64 fallopian tube cancers 64 Cardiotoxicity 64 adjuvant therapies 64 differentiated thyroid 64 fosbretabulin 64 PROSTVAC ® 64 cisplatin vinorelbine 64 docetaxel chemotherapy 64 cervical carcinoma 64 antithrombotic therapy 64 interferon ribavirin 64 Accelerated Partial Breast Irradiation 64 T1c 64 Irinotecan 64 allogeneic hematopoietic stem cell 64 methotrexate monotherapy 64 fluoropyrimidine 64 urothelial carcinoma 64 ELACYT 64 sorafenib Nexavar ® 64 TroVax ® 64 adjuvant cisplatin 64 5-FU/LV 64 Campath alemtuzumab 64 tumor histology 64 metastatic bone 64 Adjuvant Treatment 64 forodesine 64 visceral metastases 64 CALGB 64 ribavirin RBV 64 peritoneal carcinomatosis 64 randomized Phase IIb 64 lenalidomide Revlimid R 64 abiraterone acetate 64 EBRT 64 alpha 2a 64 axitinib 64 bevacizumab Avastin 64 BRIM2 64 androgen suppression therapy 64 Aplidin 64 Platinol ® cisplatin 64 adalimumab Humira 64 adenoma recurrence 64 adriamycin 64 squamous histology 64 Amrubicin 64 dasatinib 64 CTAP# Capsules 64 bevacizumab Avastin ® 64 KRAS mutation 64 standard chemotherapy regimen 64 PANVAC VF 64 exemestane Aromasin 64 chemotherapeutic regimens 64 metastatic malignant melanoma 64 Renal Cell Carcinoma RCC 64 CHOP chemotherapy 64 Mitomycin C 64 paclitaxel poliglumex 64 biologic DMARD 64 bendamustine 64 colorectal adenoma 64 portal vein thrombosis 64 recurrent glioblastoma 64 metastatic liver 64 operable breast cancer 64 decitabine 64 FDG PET 64 pulmonary metastases 64 Aflibercept 64 gastrointestinal stromal tumors GIST 64 ALA PDT 64 ThermoDox R 64 dasatinib Sprycel 64 samalizumab 64 microsphere therapy 64 androgen deprivation 64 EndoTAGTM 1 64 radiochemotherapy 64 FUSILEV enhances 64 BR.# 64 refractory ovarian cancer 64 Adjuvant Chemotherapy 64 temsirolimus 64 Bayer HealthCare Onyx Pharmaceuticals 64 Platinol ® 64 previously untreated follicular 64 mycophenolate mofetil MMF 64 pT2 64 standard chemotherapy regimens 64 FOLFOX4 64 Hematologic 64 pelvic lymphadenectomy 64 nodal metastasis 64 relapsed SCLC 64 evaluating tivozanib 63 Folfox 63 paclitaxel Taxol ® 63 5 fluorouracil leucovorin 63 ritonavir boosted 63 axillary dissection 63 APTIVUS ritonavir 63 infusional 5-FU/LV 63 epithelial tumors 63 docetaxel Taxotere ® 63 TEMODAL 63 mRCC 63 Allovectin 7 ® 63 imatinib Gleevec 63 pazopanib 63 Bevacizumab Avastin 63 HSCT 63 dose melphalan 63 Panzem NCD 63 Lenalidomide 63 docetaxel 63 riociguat 63 gefitinib 63 goserelin 63 Retreatment 63 thoracoscopic lobectomy 63 cytoreductive surgery 63 DAPT 63 Fludarabine 63 non squamous NSCLC 63 myocardial revascularization 63 farletuzumab 63 oral rivaroxaban 63 radiation sensitizer 63 gemcitabine cisplatin 63 irinotecan chemotherapy 63 chemotherapeutic regimen 63 achieved CCyR 63 hormone refractory metastatic prostate 63 metastatic colorectal 63 OvaRex MAb 63 Cimzia TM 63 motesanib diphosphate 63 CIMZIA TM 63 Taxotere ® 63 B Cell Lymphoma 63 melphalan prednisone 63 endometrial hyperplasia 63 recurrent malignant glioma 63 TACE 63 heavily pretreated 63 Torisel 63 elective PCI 63 paclitaxel Taxol R 63 Myelodysplastic Syndrome 63 bladder carcinoma 63 metastatic sarcoma 63 Pegylated Interferon 63 Phase Ib clinical 63 liver transplant recipients 63 Trastuzumab 63 F FDG PET 63 oblimersen 63 prostate carcinoma 63 cytotoxic therapy 63 platelet inhibitor 63 refractory AML 63 sorafenib tablets 63 intralesional 63 Hepatocellular Carcinoma HCC 63 dacarbazine DTIC 63 FOLFIRINOX 63 SCCHN 63 invasive candidiasis 63 Gefitinib 63 IMA# 63 peritoneal cancer 63 randomized multicenter trial 63 fludarabine cyclophosphamide 63 Gliadel Wafer 63 GAMMAGARD 63 advanced unresectable 63 Tesmilifene 63 pCR 63 Stereotactic Body Radiation Therapy 63 endometrial carcinoma 63 briakinumab 63 talabostat 63 EOquin TM 63 transarterial 63 resminostat 63 Phase 1b clinical trials 63 recurrent prostate cancer 63 CIMZIA ™ 63 metastatic neuroendocrine tumors 63 ATACAND 63 ELOXATIN 63 paclitaxel cisplatin 63 AA Amyloidosis 63 Elitek 63 visilizumab 63 hepatic metastases 63 intravenous bisphosphonates 63 Augment Injectable 63 metastatic HRPC 63 CR nPR 63 anti angiogenic agents 63 chlorambucil 63 GW# [003] 63 BRAF mutated 63 Vicinium TM 63 Afatinib 63 SABCS 63 teriflunomide 63 mapatumumab 63 Teriflunomide 63 Vandetanib 63 Adjuvant therapy 63 Xeloda ® 63 CA4P 63 SIR Spheres 63 stage IIIA 63 NSABP B 63 sipuleucel T 63 liposomal amphotericin B 63 contralateral breast 63 oral ridaforolimus 63 clinicopathological 63 sunitinib Sutent 63 Xanafide 63 novel oral anticoagulant 63 solid organ transplantation 63 radical nephrectomy 63 Bezielle 63 EGFR expressing 63 temozolomide TMZ 63 Exemestane 63 Cetuximab 63 APTIVUS R 63 rFVIIa 63 HuMax EGFr 63 Subgroup analysis 63 atherosclerotic renal artery stenosis 63 Traficet EN 63 APPRAISE 63 abacavir Ziagen 63 Cytoxan 63 histologically proven 63 Zemplar Capsules 62 GP IIb IIIa inhibitors 62 AGILECT R 62 PROCHYMAL 62 superficial bladder cancer 62 bortezomib refractory 62 androgen ablation 62 β blockers 62 alvespimycin 62 VNP#M 62 Ozarelix 62 somatostatin analog 62 Naive Patients 62 ZOLINZA 62 relapsing multiple sclerosis 62 Dacogen injection 62 tanespimycin 62 FOLFIRI 62 apremilast 62 PEG IFN 62 FOLFOX 62 curative therapy 62 aromatase inhibitor therapy 62 node metastases 62 elacytarabine 62 polycythemia vera essential thrombocythemia 62 Femara letrozole 62 anastrazole 62 dasatinib Sprycel ® 62 DCVax R 62 NATRECOR ® 62 oral clodronate 62 NovoTTF 62 APTIVUS r 62 CIMZIA TM certolizumab pegol 62 ZD# [001] 62 thromboembolic events 62 Fludara 62 deCODE ProstateCancer TM 62 lipid lowering therapy 62 Quinamed 62 unresectable stage 62 papillary thyroid carcinoma 62 Soft Tissue Sarcoma 62 RECIST Response Evaluation Criteria 62 CLARITY study 62 cytotoxic chemotherapy 62 cutaneous melanoma 62 leukemia AML 62 prospectively stratified 62 Panzem R NCD 62 recurrent glioma 62 Peginterferon 62 advanced adenomas 62 Dyloject TM 62 Natalizumab 62 Sipuleucel T 62 allogeneic transplantation 62 sargramostim 62 bortezomib Velcade 62 refractory chronic lymphocytic 62 FOLFOX6 chemotherapy regimen 62 LUX Lung 62 recurrent ovarian cancer 62 cranial irradiation 62 boosted protease inhibitor 62 Hycamtin ® 62 multicentric 62 multicenter randomized controlled 62 symptomatic VTE 62 hematopoietic cancers 62 allogeneic HSCT 62 liver metastases 62 hepatocellular carcinoma HCC 62 ipsilateral breast 62 laparoscopic radical nephrectomy 62 TLK# 62 Halaven 62 rituximab Rituxan 62 trastuzumab Herceptin ® 62 REMINYL ® 62 breast carcinoma 62 metastatic colorectal carcinoma 62 CHARM Added 62 TKI therapy 62 Chemoradiation 62 refractory CLL 62 intraperitoneal therapy 62 doxorubicin cyclophosphamide 62 RE LY 62 IV NSCLC 62 oral Xeloda 62 dose dexamethasone 62 nephron sparing surgery 62 carcinoid tumors 62 Waldenstrom macroglobulinemia 62 immunomodulatory therapy 62 cetuximab 62 RCW breast cancer 62 antiproliferative effects 62 Mitoxantrone 62 plus dexamethasone 62 TYKERB 62 allogeneic SCT 62 genotypic resistance 62 Estrogen Receptor 62 mucinous 62 Cloretazine 62 haematologic 62 alemtuzumab Campath 62 bosutinib 62 Cell Lymphoma 62 mCRC patients 62 Radical prostatectomy 62 Telintra 62 BrachySil TM 62 tipranavir 62 darunavir ritonavir 62 methotrexate therapy 62 radioiodine therapy 62 Myelofibrosis 62 neo adjuvant chemotherapy 62 sunitinib 62 Chronic Lymphocytic Leukemia CLL 62 Follicular Lymphoma 62 lapatinib Tykerb 62 ximelagatran 62 FDG PET imaging 62 ACTEMRA TM 62 radical prostatectomy RP 62 transrectal ultrasound guided 62 MVax 62 situ CIS 62 oncologic outcomes 62 follicular Non Hodgkin 62 Metastatic Melanoma 62 phase IIb study 62 tramiprosate Alzhemed TM 62 flutamide 62 multiple myeloma MM 62 EGFR mutation positive 62 distant metastasis 62 dose escalation phase 62 Vectibix monotherapy 62 temozolomide Temodar 62 ß blockers 62 CCyR 62 taxane refractory 62 radiation chemoradiation 62 interstitial brachytherapy 62 SUTENT ® 62 combretastatin A4 phosphate CA4P 62 alfa 2a 62 SLN biopsy 62 prospectively defined 62 ToGA 62 CHAMPION PCI 62 biochemical recurrence 62 LHRH agonists 62 Tumor Response 62 Unresectable 62 NeuroStar TMS Therapy 62 placebo controlled clinical 62 histologies 62 Prognostic factors 62 BENICAR HCT 62 mTOR inhibitors 62 prostate cancer mCRPC 62 KRAS mutations occur 62 percutaneous cryoablation 62 Gemcitabine 62 5 Fluorouracil 62 BEXXAR Therapeutic Regimen 62 pancreatic lung 62 node dissection 62 metastatic renal cell 62 aldosterone antagonists 62 PegIFN RBV 62 adecatumumab 62 Cloretazine ® 62 treatment naive genotype 62 colorectal carcinoma 62 Zybrestat 62 lenalidomide dexamethasone 62 OPAXIO 62 tocilizumab 62 chemo immunotherapy 62 resectable pancreatic cancer 62 immunomodulatory agents 62 TASKi3 62 atypical Hemolytic Uremic Syndrome 62 miconazole Lauriad ® 62 Castration Resistant Prostate Cancer 62 Combination therapy 62 PROSTVAC TM 62 ARIMIDEX 62 precursor lesions 62 patients evaluable 61 Phase Ib II 61 viral kinetics 61 advanced metastatic renal 61 thymoma 61 Atypical Hemolytic Uremic Syndrome 61 Vidaza azacitidine 61 5FU 61 APTIVUS 61 Cutaneous T 61 Phase #/#a trial 61 olaparib 61 Acute Myeloid Leukaemia AML 61 bortezomib Velcade R 61 Elotuzumab 61 Eculizumab 61 severe oral mucositis 61 antitumor effect 61 Proxinium TM 61 Herceptin trastuzumab 61 Enzastaurin 61 cinacalcet 61 Mycophenolate Mofetil 61 EVEREST II 61 GEM OS1 61 elotuzumab 61 anastrozole 61 metastatic androgen independent 61 TO AVOID PREGNANCY WHILE 61 lymph node involvement 61 Paraplatin ® 61 trans retinoic acid 61 prospective multicenter study 61 AVASTIN 61 Dasatinib 61 remission induction 61 BEACOPP 61 allogeneic stem cell 61 pancreatic prostate 61 PSADT 61 HBeAg positive patients 61 acyclovir Lauriad R 61 paricalcitol 61 oral Hycamtin 61 CAMMS# 61 patients undergoing CABG 61 beta blocker therapy 61 iniparib 61 progression TTP 61 imatinib therapy 61 Pharmacokinetics PK 61 multimodality therapy 61 prucalopride 61 regorafenib 61 mitoxantrone plus 61 KRAS status 61 haematologic malignancies 61 neo adjuvant 61 Myelodysplastic Syndrome MDS 61 gastrointestinal stromal tumor GIST 61 Genasense ® 61 Neulasta ® 61 evaluable patients 61 romidepsin 61 Neoadjuvant Chemotherapy 61 BRCA deficient 61 phase Ib 61 hepatic lesions 61 dose cohort 61 extracranial 61 fulvestrant 61 doublet chemotherapy 61 xenograft models 61 unresectable Stage III 61 carotid artery stenting CAS 61 ARB telmisartan 61 docetaxel cisplatin 61 SUTENT 61 distant metastases 61 etanercept Enbrel 61 HER2 overexpression 61 Tarceva erlotinib 61 Adjuvant Therapy 61 Ophena 61 evaluating Nexavar 61 Melphalan 61 minimally symptomatic 61 Temodar ® 61 immunosuppressive regimens 61 Advaxis Phase 61 ganetespib 61 TNFerade TM 61 precancerous condition 61 carboplatin 61 GOUT 61 HoLEP 61 ibandronate 61 metastatic lung cancer 61 VTE prevention 61 Fludara ® 61 relapsing remitting MS RRMS 61 Teysuno 61 Glufosfamide 61 doxorubicin docetaxel 61 systemic ALCL 61 Acute Ischemic Stroke 61 malignant ascites 61 Phase Ib study 61 cabazitaxel 61 letrozole Femara 61 antiplatelet therapy 61 iniparib BSI 61 Alessandro Riva 61 Pegasys plus Copegus 61 Phase III randomized controlled 61 G#DT 61 brain metastases 61 pegylated interferon alfa 61 mTOR inhibitor 61 carotid endarterectomy CEA 61 CR CRu 61 MabCampath 61 HGS# 61 Myocet 61 BRIM3 61 stage IIIB IV 61 dexamethasone Decadron 61 leukotriene receptor antagonist 61 autologous SCT 61 HCV SPRINT 61 vorinostat 61 myelodysplastic myeloproliferative diseases 61 epithelial ovarian cancer 61 endoscopic ultrasonography 61 pancreatic neuroendocrine tumors 61 intravesical therapy 61 eplerenone 61 RhuDex TM 61 corticosteroid therapy 61 PSA nadir 61 RhuDex R 61 epithelial ovarian 61 TNF blocker therapy 61 Erlotinib 61 Systemic Sclerosis 61 huN# DM1 61 Free Survival PFS 61 Nilotinib 61 chemotherapy FOLFOX 61 Ophena TM 61 patientswith 61 bevacizumab Avastin Genentech 61 essential thrombocythemia ET 61 aspirin clopidogrel 61 vincristine doxorubicin 61 refractory cutaneous T 61 benign prostatic hypertrophy BPH 61 coinfected patients 61 total thyroidectomy 61 histopathologic examination 61 Carfilzomib 61 preoperative staging 61 radical cystectomy 61 Tyrima 61 pretreatment serum 61 imatinib Gleevec ® 61 leiomyomas 61 balloon brachytherapy 61 virologic failure 61 non resectable metastatic 61 Kantarjian 61 resistant hormone refractory 61 lenalidomide Revlimid 61 brivaracetam 61 fluvastatin 61 plus gemcitabine 61 axillary lymph node 61 localized renal 61 IRX 2 61 advanced pancreatic neuroendocrine 61 Fluorouracil 61 allogeneic transplant 61 OHR/AVR# 61 prognostic indicators 61 gp# vaccine 61 VTE prophylaxis 61 scintigraphic 61 FASLODEX 61 oral chemotherapeutic agent 61 NCCTG N# 61 relapsed AML 61 pimecrolimus 61 EGFR tyrosine kinase inhibitor 61 TAXOTERE R 61 ASCO GI 61 budesonide foam 61 gastric adenocarcinoma 61 Raptiva r 61 azacytidine 61 deep venous thromboses 61 glufosfamide 61 Metastatic Colorectal Cancer 61 infusional 61 vidofludimus 61 ICD implantation 61 VATS lobectomy 61 Hormonal therapy 61 docetaxel Taxotere R 61 Ixempra 61 ovarian suppression 61 inoperable pancreatic cancer 61 palliative radiotherapy 61 esophagogastric 61 Bortezomib 61 AVADO 61 chemo radiotherapy 61 Alequel 61 Aptivus ® 61 HRPC 61 YERVOY 61 sustained virological response 61 metastatic castration resistant 61 EGFR HER2 61 ENGAGE AF TIMI 61 HYVET 61 blinded randomized placebo controlled 61 pamidronate 61 AVOREN 61 conformal radiotherapy 61 lymphoma subtypes 61 invasive carcinoma 61 relapsed refractory multiple myeloma 61 ovarian carcinoma 61 K ras mutations 61 taxane chemotherapy 61 Sentinel node biopsy 61 complete cytogenetic response 61 Thal Dex 61 CRLX# 61 tumor necrosis 61 Liver Metastases 61 Stage IIB 61 Panzem R 61 completely resected 61 dacarbazine chemotherapy 61 Temsirolimus 61 fluorouracil 61 refractory CTCL 61 intermittent dosing 61 hormone deprivation 61 idarubicin 61 evaluating mipomersen 61 Selective Internal 61 metastatic lymph nodes 61 MADIT CRT trial 61 hepatocellular cancer 61 Imprime PGG 61 SPRYCEL ® 61 Virulizin ® 61 RRMS patients 61 dysplastic nevi 61 NCIC CTG 61 virologic responses 61 epoetin alpha 61 lymph node metastases 61 VELCADE melphalan 61 CT Colonography 61 gastrointestinal stromal tumors 61 docetaxel prednisone 61 EGFR inhibitors 61 polyarticular 61 adjuvant trastuzumab 61 tamoxifen Nolvadex ® 61 infliximab Remicade 61 tirofiban 61 ACRIN 61 Edge STudy 61 parathyroidectomy 61 androgen independent 61 chronic GVHD 61 extrapleural pneumonectomy 61 tumor recurrence 60 Myelodysplastic Syndromes 60 tyrosine kinase inhibitors TKIs 60 undergone radical prostatectomy 60 alteplase 60 metastatic kidney 60 mammographic density 60 GVAX Pancreas Vaccine 60 Carcinoma 60 Boceprevir 60 registrational Phase 60 trastuzumab Herceptin R 60 MiCK assay 60 bevacizumab 60 dacarbazine 60 Breast conserving 60 rALLy clinical trial 60 prognostic variables 60 Nexavar sorafenib 60 Patients Receiving 60 adalimumab 60 vinorelbine 60 renal cell carcinomas 60 efalizumab 60 cetuximab Erbitux 60 pemetrexed 60 Mammosite 60 antithymocyte globulin 60 gastrointestinal stromal tumors GISTs 60 advanced HER2 positive 60 pretransplant 60 axillary node dissection 60 ruboxistaurin 60 stratifying patients 60 cranial radiation 60 abiraterone 60 endosonography 60 subgroup analyzes 60 bone scintigraphy 60 acute myeloid 60 Hodgkin lymphoma HL 60 Camptosar ® 60 noninfectious uveitis 60 MammoSite RTS 60 placebo dexamethasone 60 zalutumumab 60 Prolongs Survival 60 alkylating agent 60 ductal carcinomas 60 bleomycin 60 Triapine R 60 preoperative radiotherapy 60 haematological cancers 60 Afib 60 follicular lymphoma FL 60 Neuvenge 60 temsirolimus Torisel ® 60 unresectable 60 ZYBRESTAT TM 60 clinically meaningful efficacy 60 disease progression TTP 60 spiral computed tomography 60 Revlimid lenalidomide 60 virologic response 60 autologous hematopoietic stem cell 60 imatinib resistance 60 BARACLUDE r 60 Ceplene/IL-2 60 ASCUS 60 ACUITY trial 60 denileukin diftitox 60 endoscopic resection 60 Metastatic Prostate Cancer 60 mg/m2 dose 60 EBMT criteria 60 pediatric acute lymphoblastic 60 imatinib 60 Oral Fingolimod 60 CYPHER Stent 60 graft occlusion 60 clevidipine 60 follicular lymphomas 60 cutaneous squamous cell carcinoma 60 histological subtypes 60 cART 60 chemotherapy gemcitabine 60 urothelial cancer 60 dose cytarabine 60 topotecan 60 EORTC 60 daunorubicin 60 prophylactic cranial irradiation 60 tenofovir emtricitabine